The new MEG system will be installed at the Oxford Centre for Human Brain Activity (OHBA).
OHBA is part of the Wellcome Center for Integrative Neuroimaging (WIN), which is a multi-disciplinary facility and internationally renowned for its translational research of the human brain.
Janne Huhtala, CEO of MEGIN, said, "We are excited to continue working with OHBA's globally-accomplished team that has made significant contributions to the advancement of MEG technology with our latest advanced MEG system. TRIUX neo is a robust system for clinical and research use for significant translational research."
The TRIUX neo can detect and localize neural events that are generated in the brain with millimeter accuracy and millisecond resolution. Precise detection and localization of brain function can guide neurosurgery to prevent neurological complications and can lead to major breakthroughs in diagnostics. In addition, the new TRIUX neo completely circumvents helium loss through an integrated closed loop recycler, which will address environmental issues, economic waste and concerns for future world supplies of helium.
With the installation of the TRIUX neo and the development of advanced analysis methods, OHBA plans to develop new sensitive and specific biomarkers for neurodegenerative diseases and neuropsychiatric conditions. Ongoing clinical research projects that rely on MEG include investigations into motor neuron disease, bipolar disorder, psychosis, Alzheimer's disease, Parkinson's disease and eating disorders.
We are excited to ensure MEG is a core method within all our major translational and clinical neuroscience programmes to provide powerful and selective new biomarkers and to guide treatment development. MEG can transform translational human neuroscience. Its sensitivity to synaptic activity can reveal specific deficits in the activity patterns and communication within human brain networks related to different neurodegenerative and neuropsychiatric conditions. - Professor Kia Nobre, Director of OHBA.
The new TRIUX neo will further improve OHBA's ability to conduct game-changing research into biomarkers for neurodegenerative and neuropsychiatric disorders, an ambition shared between MEGIN and the University of Oxford.
The TRIUX neo MEG scanner is fundamentally important for the continuation of our world-leading translational research aimed at discovering and testing new treatments and procedures for people with mental health and brain disorders. It will add enormously to our ability to visualize and measure brain activity - and will support the work of researchers both within the Department and the wider University. - Professor John Geddes, Director of the NIHR Oxford Health Biomedical Research Centre and Head of Department of Psychiatry.